BC Platforms partners with European Genomics Service Provider Center Life & Brain for SNP genotyping and analysis market

 

SNP Genotyping and Analysis Market

The growing incidence and prevalence of genetic disorders are supporting the growth of the global SNP genotyping and analysis market. For instance, according to the Summary of the Cystic Fibrosis Foundation Patient Registry, 2003–2018, the number of people with cystic fibrosis increased from 21,421 in 2003 to 30,775 in 2018. Increasing adoption of a strategic alliance among key players is again fostering the growth of the SNP genotyping and analysis market. For instance, in April 2020, Indivumed GmbH, an oncology company, launched the Oncology Alliance for Individualized Medicine, an international collaborative alliance to advance personalized medicine in cancer through IndivuType, the company’s multi-omics database. Growing technological advancement is another key factor fostering the growth of the market.

The field of SNP or Single Nucleation Polymorphism genomics is a method to study and profile the genetic differences of SNPs along with testing individuals against a reference panel of genetic variants. It is still in its early days of development and research but has already produced many important advances over the last decade. SNP genomics has proven to be an effective way to study the human genome by identifying individual genetic differences that may affect disease states or traits. These tests are currently being used in a number of different settings, including clinical genomics, experimental genetics, and public health. As time goes on we will undoubtedly see even more progress made using this method of genetic analysis.

Major players operating in the global SNP genotyping and analysis market include LGC Limited, Fluidigm Corporation, Illumina, Inc., Life Technologies Corporation, PREMIER Biosoft, Thermo Fisher Scientific, and Sequenom, Inc.

North America is expected to dominate the global SNP genotyping and analysis market and this is attributed to the high prevalence of genetic disorder in the region which is creating demand for genotyping. According to the National Institutes of Health, about 1 in 200,000 people in the United States are diagnosed with syndrome A each year. An estimated 15,000 people worldwide were diagnosed with syndrome B last year.

Key Developments:

1.      In July 2019, Thermo Fisher Scientific launched three new Applied Biosystems AgriSeq targeted genotyping by sequencing solutions that will allow customers to genotype canines and felines.

2.      In April 2020, Researchers from Jung P & C Institute, Inc., South Korea, used Bayesian methods under different genotyping platforms to perform genomic analysis in Korean Duroc pigs.

3.      In December 2019, BC Platforms partners with European Genomics Service Provider Center Life & Brain to expand genotyping services across Europe


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

Increased Prevalence of Chronic Diseases and Stem Cell Therapy R&D to Drive Stem Cell Assay Market Growth